# Congressional stock trades in NBIX (Neurocrine Biosciences Inc)

Congressional stock trades in Neurocrine Biosciences Inc (NBIX) from House and Senate STOCK Act filings. See which members of Congress bought or sold, disclosed amounts, and filing dates.

- Industry: Biological Products, (No Diagnostic Substances)
- Last close: $146.23
- Price updated: Sep 19, 2026
- Total congressional trades: 2
- Politicians trading: 1
- Last traded: Jun 17, 2025
- Source: https://tryglasshouse.ai/companies/NBIX.md

## Trading History

- Page: 1 of 1
- Results: 2 of 2
- Pagination query parameter: `page`

## 1. Lisa C. McClain

- Member: Republican, House
- Transaction: Sell, $1,001 - $15,000
- Dates: traded Jun 17, 2025, disclosed Aug 13, 2025
- Market context: $124.88 at trade, $146.23 current (+17.10%)
- Politician: https://tryglasshouse.ai/politicians/M001136.md
- Record: https://tryglasshouse.ai/trades/312e8773-b4c0-427e-8cf5-242d981ab172.md

## 2. Lisa C. McClain

- Member: Republican, House
- Transaction: Buy, $1,001 - $15,000
- Dates: traded Jun 11, 2025, disclosed Aug 13, 2025
- Market context: $124.17 at trade, $146.23 current (+17.77%)
- Politician: https://tryglasshouse.ai/politicians/M001136.md
- Record: https://tryglasshouse.ai/trades/3832342f-11ad-4b45-a5ff-e89ce9a2c67c.md



## About Neurocrine Biosciences Inc

Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.

Prices and percentage changes are market context, not portfolio returns. This information is not financial advice.